Abiraterone, a drug used to treat prostate cancer, can block nuclear accumulation of androgen receptors (ARs) which consequently suppresses expression of cyp17a1 (Giatromanolaki et al., 2019). This evidence concerns the gene CYP17A1 and Familial prostate cancer.